Patient characteristics
. | Assigned TM Dose (mg/day) . | . | . | Total . | ||
---|---|---|---|---|---|---|
. | 90 . | 105 . | 120 . | . | ||
No. of patients | 6 | 5 | 7 | 18 | ||
Sex (M/F) | 3/3 | 1/4 | 6/1 | 10/8 | ||
Mean age (SD) (yrs) | 64 (12) | 60 (12) | 53 (17) | 59 (14) | ||
Primary Tumor | ||||||
Breast | 2 | 2 | 0 | 4 | ||
Colon | 0 | 1 | 0 | 1 | ||
Lung | 1 | 0 | 0 | 1 | ||
Melanoma | 0 | 0 | 1 | 1 | ||
Pancreas | 0 | 1 | 0 | 1 | ||
Prostate | 2 | 0 | 0 | 2 | ||
Angiosarcoma | 0 | 0 | 2 | 2 | ||
Chondrosarcoma | 0 | 1 | 0 | 1 | ||
Nasopharyngeal tumor | 0 | 0 | 1 | 1 | ||
Hemangioendothelioma | 0 | 0 | 1 | 1 | ||
Renal tumor | 1 | 0 | 2 | 3 | ||
Baseline | ||||||
Baseline Cp mean | 52.6 | 49.3 | 42.7 | 47.8 | ||
Baseline Cp range | 36.6–74.1 | 38.1–65.0 | 31.9–52.7 | 31.9–74.1 | ||
Baseline Hct mean | 31.9 | 37.2 | 41.9 | 37.3 | ||
Baseline Hct range | 26.6–35.6 | 33.8–42.5 | 35.4–45.7 | 26.6–45.7 |
. | Assigned TM Dose (mg/day) . | . | . | Total . | ||
---|---|---|---|---|---|---|
. | 90 . | 105 . | 120 . | . | ||
No. of patients | 6 | 5 | 7 | 18 | ||
Sex (M/F) | 3/3 | 1/4 | 6/1 | 10/8 | ||
Mean age (SD) (yrs) | 64 (12) | 60 (12) | 53 (17) | 59 (14) | ||
Primary Tumor | ||||||
Breast | 2 | 2 | 0 | 4 | ||
Colon | 0 | 1 | 0 | 1 | ||
Lung | 1 | 0 | 0 | 1 | ||
Melanoma | 0 | 0 | 1 | 1 | ||
Pancreas | 0 | 1 | 0 | 1 | ||
Prostate | 2 | 0 | 0 | 2 | ||
Angiosarcoma | 0 | 0 | 2 | 2 | ||
Chondrosarcoma | 0 | 1 | 0 | 1 | ||
Nasopharyngeal tumor | 0 | 0 | 1 | 1 | ||
Hemangioendothelioma | 0 | 0 | 1 | 1 | ||
Renal tumor | 1 | 0 | 2 | 3 | ||
Baseline | ||||||
Baseline Cp mean | 52.6 | 49.3 | 42.7 | 47.8 | ||
Baseline Cp range | 36.6–74.1 | 38.1–65.0 | 31.9–52.7 | 31.9–74.1 | ||
Baseline Hct mean | 31.9 | 37.2 | 41.9 | 37.3 | ||
Baseline Hct range | 26.6–35.6 | 33.8–42.5 | 35.4–45.7 | 26.6–45.7 |